Castagneto B.,San Giacomo Hospital Novi Ligure |
Stevani I.,San Giacomo Hospital Novi Ligure |
Giorcelli L.,San Giacomo Hospital Novi Ligure |
Montefiore F.,San Giacomo Hospital Novi Ligure |
And 3 more authors.
Medical Oncology | Year: 2011
The prognosis for patients with renal cell carcinoma is very poor, with a five-year survival rate of less than 10%. Sorafenib is an orally administered multikinase inhibitor that blocks intracellular kinases in the Raf/MEK/ERK pathway involved in tumor proliferation, and also kinases responsible for angiogenesis, including VEGFr-2, VEGFr-3, Flt-3, PDGFr-β and c-KIT. As a consequence of its limited renal clearance, sorafenib appears to be suitable for patients with advanced kidney cancer and terminal renal failure. The case of a 72-year-old male patient on hemodialysis and receiving sorafenib treatment for mRCC is reported. © 2010 Springer Science+Business Media, LLC. Source